PYRIDINE[3,4-b] PYRAZINONES

PYRIDINE[3,4-b] PYRAZINONES

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R2, R6A, R6B and R8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: JACOBSEN ERIC JON, ROGIER DONALD JOSEPH JR, TOLLEFSON MICHAEL BRENT, HEASLEY STEVEN EDWARD, WALKER JOHN KEITH, MISCHKE BRENT VIRGIL, HUGHES ROBERT O, BELL ANDREW SIMON, OWEN DAFYDD RHYS, PHILLIPS CHRISTOPHER, PALMER MICHAEL JOHN, MOLYNEAUX JOHN MAJOR, FRESKOS JOHN NICHOLAS, MOON JOSEPH BLAIR, FOBIAN YVETTE MARLENE, BROWN DAVID GRAHAM, MADDUX TODD MICHAEL, BROWN DAVID LOUIS
Format: Patent
Sprache:eng ; srp
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R2, R6A, R6B and R8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed. Otkrivena su jedinjenja i farmaceutski prihvatljive soli jedinjenja, pri čemu jedinjenja imaju strukturu Formule I: gde su R2,R6A, R6B i R8 kako je definisano u specifikaciji. Takode su otkrivene odgovarajuće farmaceutske kompozicije, postupci lečenja, postupci sinteze i međuproizvodi.